

# Documenting the Value of Care for Rheumatoid Arthritis, Analogous to Hypertension, Diabetes, and Hyperlipidemia: Is Control of Individual Patient Self-Report Measures of Global Estimate and Physical Function More Valuable Than Laboratory Tests, Radiographs, Indices, or Remission Criteria?



Recent recommendations for treatment of rheumatoid arthritis (RA) include “treat-to-target” with a “primary target...a state of clinical remission”<sup>1</sup>. Remission is now a realistic target in RA, because patient status is substantially better than in previous decades in most developed countries<sup>2</sup>. Capacity to induce remission may be an effective rationale for support of aggressive treatment with expensive therapies to insurance company and government payers.

The concept of “treat-to-target” was developed over the years in other chronic diseases, notably hypertension<sup>3,4</sup>, diabetes<sup>5</sup>, and hyperlipidemia<sup>6</sup>. The basis of treat-to-target was not “remission,” a state that may often be possible, but as in RA, usually requires continued lifelong medication. The target, in other diseases, involves “tight control” of a “gold standard” biomarker of dysregulation — elevated blood pressure, serum glucose, or serum cholesterol — to a lower level that results in improved quality of life and reduction of premature mortality rates. Such a target — not a state of remission — provides a strong rationale for aggressive treatment.

RA differs substantially from hypertension, diabetes, or hyperlipidemia in that there is no single, gold standard biomarker (or any other measure) for diagnosis, management, or prognosis in all individual patients. Biomarkers are of unquestioned importance in RA to understand pathogenesis and develop new therapies: Biological agents would not be available without them. However, biomarkers are limited in clinical application to diagnosis, management, and prognosis of RA:

*Diagnosis.* Forty percent of new patients have normal erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)<sup>7,8</sup>, and > 30% test negative for rheumatoid factor or anti-citrullinated protein antibodies (ACPA)<sup>9</sup>.

*Management.* Clinical decisions in RA are based more on a patient history and physical examination than on biomarkers; in contrast, biomarkers dominate clinical decisions in many chronic diseases, and may include vital signs (e.g., blood pressure in hypertension); laboratory tests (e.g., hemoglobin A1c in diabetes); imaging (e.g., computed tomographic scan in pulmonary fibrosis), or other ancillary studies (e.g., endoscopy in inflammatory bowel disease)<sup>10</sup>.

*Prognosis.* The most significant markers for future quality of life and premature mortality in RA are not laboratory tests, radiographs, indices, or remission criteria, but individual patient self-report measures of patient global estimate of status or physical function<sup>11</sup>.

In the absence of a single gold standard biomarker (or any measure) applicable to each individual patient with RA<sup>12</sup>, pooled indices<sup>13</sup> are needed to assess and monitor clinical status quantitatively, and to provide quantitative remission criteria. These indices are based on a core data set for RA<sup>14</sup> of 7 measures: 3 from patient self-report, 3 from physical examination, but only 1 laboratory test — ESR or CRP — reflecting limitations of biomarkers and the prominence of patient history and physical examination in

---

See Gain in QALY in patients with RA during one year of biological therapy, *page 1479*

RA<sup>10</sup>. Remission according to Disease Activity Score with 28 joint count (DAS28)<sup>15</sup>, Simplified Disease Activity Index (SDAI)<sup>16</sup>, Clinical Disease Activity Index (CDAI)<sup>16</sup>, and Routine Assessment of Patient Index Data (RAPID3)<sup>17</sup> has been described. More recently, more stringent “Boolean” criteria, as well as SDAI score  $\leq 3.3$ , have been advocated by a committee of the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR)<sup>18,19</sup>.

The highest levels of remission reported in RA are seen in clinical trials of a treat-to-target strategy<sup>20,21,22,23,24,25</sup> (Table 1). However, in most series from usual clinical care, only 6–33% of patients met even the least stringent DAS28 remission criteria<sup>17,26,27,28,29,30,31,32</sup> (Table 1). Therefore, an important, if not critical, task for the rheumatology community is to document effective rheumatology care although only a minority of patients reach the stated goal of clinical remission. This goal might be met more effectively

by analyzing efforts to control the most significant individual core data set measures to achieve improved quality of life and reversal of premature mortality — patient global estimate and physical function on a patient questionnaire — rather than by focusing on indices or remission.

A report by Linde, *et al*<sup>33</sup> in this issue of *The Journal* documents the value of a patient global estimate of status to explain improvement in quality of life associated with treatment of RA. Among the 4 measures of the DAS28, swollen and tender joint counts were less significant, CRP was not at all significant, while patient global estimate was most significant to explain improvement in quality of life during treatment with biological therapies. Their report extends impressive contributions from the Danish community to international rheumatology, including much information about biological therapies in usual care from the comprehensive DANBIO registry<sup>34</sup>, and the Ciclosporine, Methotrexate, Steroid in RA (CIMESTRA) trial<sup>24</sup>, in which

Table 1. Prevalence of remission in selected published reports of rheumatoid arthritis (RA) clinical trials following a tight control strategy and RA clinical cohorts, 1999–2013\*.

Author, Year, (Reference)	Patients	Prevalence of Remission; Criteria
Treatment strategy clinical trials		
Möttönen, 1999 <sup>20</sup>	Finnish RA Combination Therapy (FIN-RACo) trial	25% combination therapy; ACR 1981; 11% single-drug therapy; ACR 1981
Grigor, 2004 <sup>21</sup>	Tight Control for Rheumatoid Arthritis (TICORA) trial; single-blind RCT	65% intensive group; DAS; 16% usual care group; DAS
Verstappen, 2007 <sup>22</sup>	Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA) study; open-label strategy trial	50% intensive group; Utrecht criteria*; 37% conventional group Utrecht criteria*
Klarenbeek, 2011 <sup>23</sup>	BehandelStrategien (BeSt) or “treatment strategies” trial	23% drug-free remission
Hetland, 2012 <sup>24</sup>	Ciclosporine, Methotrexate, Steroid in RA (CIMESTRA)	56%; Boolean; 78%; DAS28
Wevers-de Boer, 2012 <sup>25</sup>	Induction therapy with MTX and Prednisone in Rheumatoid Or Very Early arthritic Disease (IMPROVED) trial; 2-step treatment strategy study in Dutch early arthritis patients	60%; Boolean
Clinical cohorts		
van der Woude, 2009 <sup>26</sup>	Leiden Early Arthritis Clinic (EAC) and British Early Rheumatoid Arthritis Study (ERAS)	21.4% Leiden EAC; modified ACR 15%; Leiden EAC; DMARD-free; 9.4% ERAS; DMARD-free
Shahouri, 2011 <sup>27</sup>	US Department of Veterans Affairs RA (VARA) registry Arthritis and Rheumatology Clinics of Kansas (ARCK)	24.0% VARA; DAS28; 7.0% VARA; Boolean; 28.3% ARCK; DAS28; 6.9% ARCK; CDAI
de Punder, 2012 <sup>28</sup>	Dutch Rheumatoid Arthritis Monitoring (DREAM) biologic registry	6%; DAS28
Prince, 2012 <sup>29</sup>	Brigham and Women’s Rheumatoid Arthritis Sequential Study (BRASS)	31%; DAS28 < 2.6; 10%; Boolean
Castrejón, 2013 <sup>17</sup>	Etude et Suivi des Polyarthrites Indifférenciées Récentes (ESPOIR) French early arthritis cohort	32.5%; DAS28; 12.9%; Boolean
Navarro-Millan, 2013 <sup>30</sup>	Consortium of Rheumatology Researchers of North America (CORRONA), 2001–2011	8%; Boolean
Thiele, 2013 <sup>31</sup>	German Collaborative Centers, 2007–2009	28%; DAS28; 7%; Boolean

\* Where a study reported remission according to multiple criteria, the criteria with the highest and lowest percentages of patients in remission are presented.

\* Utrecht criteria for remission = no swollen joint, and at least 2 of the following: TJC  $\leq 3$ , erythrocyte sedimentation rate  $\leq 20$  mm/h and visual analog scale general well being  $\leq 20$  mm<sup>22</sup>. DAS28: Disease Activity Score 28 joint; MTX: methotrexate; ACR: American College of Rheumatology; DMARD: disease-modifying antirheumatic drugs; CDAI: Clinical Disease Activity Index.

56% of patients met Boolean and 78% DAS28 remission criteria after 5 years<sup>24</sup> (Table 1).


A measure of quality of life is a criterion used by insurance companies and government payers to estimate the potential value of biological therapies for a patient with RA. Control of patient global estimate, rather than joint counts, radiographic scores, or laboratory tests, could be more valuable to justify expensive RA treatments. Remission might become a valuable surrogate in the future if it was commonly achieved, say, in two-thirds of patients in usual care, rather than in one-third (the maximum reported rate today).

Another important possible target for control using an individual RA patient questionnaire measure involves physical function and longterm mortality. The natural history of RA involves the shortening of lifespan by about a decade, comparable to hypertension and diabetes<sup>35,36</sup>. Further, diseases such as systemic lupus erythematosus (SLE)<sup>37</sup>, polymyositis<sup>38</sup>, vasculitis, and systemic sclerosis are associated with increased mortality rates, comparable to or greater than most forms of cardiovascular and neoplastic


diseases<sup>39,40</sup>. RA and other inflammatory rheumatic diseases should be monitored routinely for 5-year survival and other mortality outcomes, as is the case for cardiovascular and neoplastic diseases.

In RA, the most significant predictor of mortality is a patient questionnaire measure of physical function — not a laboratory test or other biomarker — documented initially almost 30 years ago<sup>35,41</sup>, confirmed in a second cohort observed from 1985–1990<sup>42</sup>, and in 15 of 16 reported RA cohorts<sup>43</sup> (Figure 1). Further, a measure of physical function on a patient questionnaire is more significant than any laboratory test or radiographic score to predict costs, work disability, or even joint replacement surgery<sup>11</sup>. The only outcome predicted most significantly by radiographs or laboratory tests is radiographic progression<sup>44</sup>, which appears less relevant to the other longterm outcomes noted than patient questionnaire scores. Even if premature mortality is falling, the relative importance of physical function likely remains; in a study in Finland, physical function on Health Assessment Questionnaire (HAQ) predicted 5-year mortality at higher levels than smoking in

### A Prognostic Markers for Survival in 3 Diseases over 9-10 Years: 1970s



### B Prognostic Markers for Survival in Rheumatoid Arthritis: 1985-1990



### C Prognostic Markers for Survival in Rheumatoid Arthritis: 53 Studies




Figure 1. (A) Nine- to 10-year survival according to quantitative markers in 3 chronic diseases in the 1970s. From Pincus and Callahan. *J Rheumatol* 1986;13:841-5<sup>35</sup>; and Pincus, et al. *Arthritis Rheum* 1984;27:864-72<sup>41</sup>; with permission. (B) Survival over 5 years (1985–1990) in 206 patients with RA according to rheumatoid factor, functional status on a Modified Health Assessment Questionnaire (MHAQ), radiographic score, and erythrocyte sedimentation rate. From Callahan, et al. *Arthritis Care Res* 1997<sup>42</sup>; with permission. (C) Significance of 8 variables as predictors of mortality. In a review of 84 reports concerning mortality in RA, 53 cohorts presented predictors of mortality<sup>43</sup>. For each variable, n = the number of reports that included the variable, and bars indicate the percentage of those reports in which the variable was a significant predictor of mortality in multivariate analyses (black), in univariate analyses (dotted), or not significant (white). From Sokka, et al. *Clin Exp Rheumatol* 2008;26 Suppl 51:S35-S61; with permission.

individuals in the general population who had no life-threatening diseases<sup>45</sup>.

Possible documentation of control of physical function in RA to achieve a lower level might provide a marker for improved longterm outcomes, including improved survival. This would be analogous to documentation of improved survival based on control of blood pressure in hypertension<sup>3,4</sup>, serum glucose in diabetes<sup>5</sup>, or serum cholesterol in hyperlipidemia<sup>6</sup>. Reduction of mortality may be regarded as a universal goal of all medical care, usually understood by payers for medical services more easily than any other outcome.

It appears likely that improved physical function would be associated with improved survival, based on pioneering studies of improved mortality outcomes associated with methotrexate treatment by Krause<sup>46</sup> and Choi<sup>47</sup>, as well as with biologic agents by Jacobsson<sup>48</sup>. Improvement in physical function scores with these agents is well established. However, it remains to be documented that improvement of HAQ or Multidimensional HAQ (MDHAQ) score in an individual patient will result directly in a significant change in mortality outcomes, analogous to studies in other chronic diseases<sup>23,24</sup>.

Another difference between RA and other chronic diseases (in addition to the absence of a gold standard biomarker) is that RA is not associated with acute emergencies and sudden death, as may be seen in hypertension and diabetes. It might therefore be suggested that the absence of possible acute catastrophe in RA might limit support for aggressive treatment, based on control of physical function to improve survival. However, a major activity of contemporary clinical medicine involves treatment, with statins, of apparently normal, usually asymptomatic, individuals who have elevated serum cholesterol. The rationale is almost entirely based on epidemiologic data that control of serum cholesterol is associated with improved survival, rather than based on clinical signs or symptoms<sup>6</sup>; although control of a biomarker is accepted more readily than a patient questionnaire score as an important measure by most physicians (including most rheumatologists).

Patient global estimate and physical function may be assessed easily on HAQ<sup>49</sup> or MDHAQ<sup>50</sup>, as 2 of the 7 RA core data set<sup>14</sup> measures. However, quantitative clinical data from a patient history in the form of a patient self-report questionnaire, and even from physical examination in the form of joint counts and physician global estimate, have not been incorporated by most clinical rheumatologists, at least in the United States<sup>51</sup>. Further, most training programs continue to neglect these quantitative clinical measures. Indeed, the only quantitative data in the medical records of most RA patients of most rheumatologists — even today — are laboratory tests, despite their limitations in clinical decision and prognosis. Therefore, current medical records of most rheumatologists could not be used to document

improved clinical status for most patients with RA, or even remission; much less to achieve control of the most significant prognostic markers.

Completing the HAQ or MDHAQ creates no extra work for the doctor, nor interference with patient flow, when distributed by the receptionist in a cheerful manner to each patient at each visit and/or completed by patients electronically in the waiting area. An MDHAQ helps the patient prepare for the visit, improves doctor-patient communication, and saves time for the doctor, with a 10–15 second overview of information from a self-report joint count, review of systems, and recent medical history that would otherwise require 10–15 minutes of conversation to elicit<sup>52</sup>. Patient questionnaires do not prevent collection of any additional quantitative data such as joint counts, laboratory tests, or radiographic scores; however, longterm databases concerning RA patients, such as DANBIO<sup>34</sup>, are needed to document possible improvements in quality of life according to better control of patient global estimates, and possible improvements in longterm mortality according to better of physical function.

Most rheumatologists may do as much for their patients as other specialists, but rheumatology is underappreciated by the general medical community and the general public; not to mention under-reimbursed. Epidemiologic evidence of improved quality of life and survival after control of the patient global estimate and physical function could facilitate reimbursement by insurance and government payers.

If remission criteria were met by the majority of patients, support for expensive biological therapies in RA might be likely. However, because most people with RA are not in remission, other documentation of the value of treatment is needed. Patient global estimate and physical function are far more informative than laboratory tests, joint counts, radiographs, indices, or remission criteria to recognize improved RA outcomes. Routine collection of these quantitative data on patient questionnaires in the infrastructure of clinical care to document control to achieve more favorable values, rather than simple notation of *gestalt* impressions by the physician, would appear to be an intellectual and ethical responsibility to our patients with RA.

**THEODORE PINCUS, MD;**

**ISABEL CASTREJÓN, MD;**

**YUSUF YAZICI, MD,**

New York University School of Medicine and  
NYU Hospital for Joint Diseases,  
New York, NY, USA

Address correspondence to Dr. Pincus; E-mail: tedpincus@gmail.com

## REFERENCES

1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis* 2010;69:631-7.

2. Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. *Arthritis Rheum* 2005;52:1009-19.
3. Veterans Administration Cooperative Study on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. *JAMA* 1967;202:1028-34.
4. Veterans Administration Cooperative Study on Antihypertensive Agent. Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. *JAMA* 1970;213:1143-50.
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977-86.
6. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. *J Am Coll Cardiol* 2008;52:1769-81.
7. Keenan RT, Swearingen CJ, Yazici Y. Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. *Clin Exp Rheumatol* 2008;26:814-9.
8. Sokka T, Pincus T. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%–45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. *J Rheumatol* 2009;36:1387-90.
9. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. *Ann Intern Med* 2007;146:797-808.
10. Castrejón I, McCollum L, Durusu Tanriover M, Pincus T. Importance of patient history and physical examination in rheumatoid arthritis compared to other chronic diseases: Results of a physician survey. *Arthritis Care Res* 2012;64:1250-5.
11. Pincus T. A multidimensional health assessment questionnaire (MDHAQ) for all patients with rheumatic diseases to complete at all visits in standard clinical care. *Bull NYU Hosp Jt Dis* 2007;65:150-60.
12. Pincus T, Yazici Y, Sokka T. Complexities in assessment of rheumatoid arthritis: absence of a single gold standard measure. *Rheum Dis Clin North Am* 2009;35:687-97.
13. Goldsmith CH, Smythe HA, Helewa A. Interpretation and power of pooled index. *J Rheumatol* 1993;20:575-8.
14. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. *Arthritis Rheum* 1993;36:729-40.
15. Prevoe MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995;38:44-8.
16. Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. *Clin Exp Rheumatol* 2005;23:S100-S108.
17. Castrejón I, Dougados M, Combe B, Guillemin F, Fautrel B, Pincus T. Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? Possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort. *J Rheumatol* 2013;40:386-93.
18. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. *Arthritis Rheum* 2011;63:573-86.
19. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. *Ann Rheum Dis* 2011;70:404-13.
20. Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. *Lancet* 1999;353:1568-73.
21. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. *Lancet* 2004;364:263-9.
22. Verstappen SMM, Jacobs JWG, van der Veen MJ, Heurkens AHM, Schenk Y, Ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). *Ann Rheum Dis* 2007;66:1443-9.
23. Klarenbeek NB, Guler-Yuksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJ, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. *Ann Rheum Dis* 2011;70:1039-46.
24. Hetland ML, Ostergaard M, Ejbjerg B, Jacobsen S, Stengaard-Pedersen K, Junker P, et al. Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP. *Ann Rheum Dis* 2012;71:851-6.
25. Wevers-de Boer K, Visser K, Heimans L, Ronday HK, Molenaar E, Groenendaal JH, et al. Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). *Ann Rheum Dis* 2012;71:1472-7.
26. van der Woude D, Young A, Jayakumar K, Mertens BJ, Toes RE, van der Heijde D, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. *Arthritis Rheum* 2009;60:2262-71.
27. Shahouri SH, Michaud K, Mikuls TR, Caplan L, Shaver TS, Anderson JD, et al. Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. *Arthritis Rheum* 2011;63:3204-15.
28. de Punder YM, Fransen J, Kievit W, Houtman PM, Visser H, van De Laar MA, et al. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. *Rheumatology (Oxford)* 2012;51:1610-7.
29. Prince FH, Bykerk VP, Shadick NA, Lu B, Cui J, Frits M, et al. Sustained rheumatoid arthritis remission is uncommon in clinical practice. *Arthritis Res Ther* 2012;14:R68.
30. Navarro-Millan I, Chen L, Greenberg JD, Pappas DA, Curtis JR. Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients. *Semin Arthritis Rheum* 2013 Jun 3, [epub ahead of print]
31. Thiele K, Huscher D, Bischoff S, Spathling-Mestekemper S, Backhaus M, Aringer M, et al. Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. *Ann Rheum Dis* 2013;72:1194-9.
32. Pincus T, Castrejón I, Bergman MJ, Yazici Y. Treat-to-target: not as

- simple as it appears. *Clin Exp Rheumatol* 2012;30 Suppl 73: S10-S20.
33. Linde L, Sorensen J, Ostergaard M, Hetland ML. Gain in quality adjusted life years in patients with rheumatoid arthritis during one year of biological therapy — a prospective study in clinical practice. *J Rheumatol* 2013;40:1479-86.
  34. Hetland ML. DANBIO — powerful research database and electronic patient record. *Rheumatology (Oxford)* 2011;50:69-77.
  35. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously — predictive markers, socioeconomic status and comorbidity. *J Rheumatol* 1986;13:841-5.
  36. Pincus T, Gibofsky A, Weinblatt ME. Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. *Arthritis Rheum* 2002;46:851-4.
  37. Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. *Medicine (Baltimore)* 1971;50:85-95.
  38. Medsger TA Jr, Robinson H, Masi AT. Factors affecting survivorship in polymyositis: a life-table study of 124 patients. *Arthritis Rheum* 1971;14:249-58.
  39. Callahan LF, Pincus T. Mortality in rheumatic diseases. *Arthritis Care Res* 1995;8:229-41.
  40. Sokka T, Pincus T. Mortality in rheumatic diseases. *Clin Exp Rheumatol* 2008;26 Suppl 51:S1-S144.
  41. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. *Arthritis Rheum* 1984;27:864-72.
  42. Callahan LF, Pincus T, Huston JW III, Brooks RH, Nance EP Jr, Kaye JJ. Measures of activity and damage in rheumatoid arthritis: Depiction of changes and prediction of mortality over five years. *Arthritis Care Res* 1997;10:381-94.
  43. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. *Clin Exp Rheumatol* 2008;26 Suppl 51:S35-S61.
  44. Olsen NJ, Callahan LF, Brooks RH, Nance EP, Kaye JJ, Stastny P, et al. Associations of HLA-DR4 with rheumatoid factor and radiographic severity in rheumatoid arthritis. *Am J Med* 1988;84:257-64.
  45. Sokka T, Pincus T. Poor physical function, pain and limited exercise: risk factors for premature mortality in the range of smoking or hypertension, identified on a simple patient self-report questionnaire for usual care. *BMJ Open* 2011 June 18;1:e000070.
  46. Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. *Arthritis Rheum* 2000;43:14-21.
  47. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. *Lancet* 2002;359:1173-7.
  48. Jacobsson LTH, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. *Ann Rheum Dis* 2007;66:670-5.
  49. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum* 1980;23:137-45.
  50. Pincus T, Sokka T, Kautiainen H. Further development of a physical function scale on a multidimensional health assessment questionnaire for standard care of patients with rheumatic diseases. *J Rheumatol* 2005;32:1432-9.
  51. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. *Arthritis Care Res (Hoboken)* 2012;64:640-7.
  52. Pincus T, Skummer PT, Grisanti MT, Castrejón I, Yazici Y. MDHAQ/RAPID3 can provide a roadmap or agenda for all rheumatology visits when the entire MDHAQ is completed at all patient visits and reviewed by the doctor before the encounter. *Bull NYU Hosp Jt Dis* 2012;70:177-86.
- J Rheumatol* 2013;40:1469–74;doi:10.3899/jrheum.130736